These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36450511)

  • 1. [The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
    Honda A; Ishii I
    Yakugaku Zasshi; 2022; 142(12):1335-1343. PubMed ID: 36450511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease.
    Kamata S; Honda A; Ishii I
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
    Honda A; Kamata S; Akahane M; Machida Y; Uchii K; Shiiyama Y; Habu Y; Miyawaki S; Kaneko C; Oyama T; Ishii I
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Honda A; Kamata S; Satta C; Machida Y; Uchii K; Terasawa K; Nemoto A; Oyama T; Ishii I
    Biol Pharm Bull; 2021; 44(9):1210-1219. PubMed ID: 34471049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor.
    Kamata S; Honda A; Ishikawa R; Akahane M; Fujita A; Kaneko C; Miyawaki S; Habu Y; Shiiyama Y; Uchii K; Machida Y; Oyama T; Ishii I
    Antioxidants (Basel); 2023 Jul; 12(8):. PubMed ID: 37627519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease.
    Choudhary NS; Kumar N; Duseja A
    J Clin Exp Hepatol; 2019; 9(6):731-739. PubMed ID: 31889755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatoprotective effects of ZLY16, a dual peroxisome proliferator-activated receptor α/δ agonist, in rodent model of nonalcoholic steatohepatitis.
    Zhou Z; Deng L; Hu L; Ren Q; Cai Z; Wang B; Li Z; Zhang L
    Eur J Pharmacol; 2020 Sep; 882():173300. PubMed ID: 32592770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review.
    Tidwell J; Balassiano N; Shaikh A; Nassar M
    World J Hepatol; 2023 Aug; 15(8):1001-1012. PubMed ID: 37701920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
    Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
    Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
    Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
    Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
    Qiu YY; Zhang J; Zeng FY; Zhu YZ
    Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies.
    Pramanik S; Pal P; Ray S
    World J Methodol; 2024 Jun; 14(2):91319. PubMed ID: 38983664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
    Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.
    Polyzos SA; Kang ES; Boutari C; Rhee EJ; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154203. PubMed ID: 32151660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH).
    Westerouen Van Meeteren MJ; Drenth JPH; Tjwa ETTL
    Expert Opin Investig Drugs; 2020 Feb; 29(2):117-123. PubMed ID: 31523999
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery of novel modulators for the PPARα (peroxisome proliferator activated receptor α): Potential therapies for nonalcoholic fatty liver disease.
    Yu DD; Van Citters G; Li H; Stoltz BM; Forman BM
    Bioorg Med Chem; 2021 Jul; 41():116193. PubMed ID: 34022528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An insight into the role of telmisartan as PPAR-γ/α dual activator in the management of nonalcoholic fatty liver disease.
    Devan AR; Nair B; Kumar AR; Nath LR
    Biotechnol Appl Biochem; 2022 Apr; 69(2):461-468. PubMed ID: 33578449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
    Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
    Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RLA8-A New and Highly Effective Quadruple PPAR-
    Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
    J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.